Kees Hovingh, MD, PhD, MBA

Kees Hovingh, MD, PhD, MBA, is a Venture Partner at Forbion. He is a distinguished physician and scientist with extensive expertise in vascular medicine, lipid disorders, diabetes, obesity and other metabolic diseases. 

He previously joined Novo Nordisk in 2019 and served as Chief Scientific Advisor, helping shape research and development strategy, evaluate clinical value across the product lifecycle and assess external opportunities, including the acquisition of Corvidia. 

He also served on early- and late-stage governance boards and steering committees for several major outcome trials. Kees has also held senior academic and clinical positions at Amsterdam University Medical Centre, where he was Professor of Vascular Medicine, co-chaired the Department of Internal Medicine and led its clinical trial unit and co-authored more than 400 publications. Earlier in his career, he completed a postdoctoral fellowship in genetics at Harvard Medical School.